Grazoprevir
Grazoprevir (MK-5172) is a drug approved for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, following promising results in Phase II when used in combination with the NS5A replication complex inhibitor elbasvir, either with or without ribavirin. Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets. It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications.
primaryTopic
Grazoprevir
Grazoprevir (MK-5172) is a drug approved for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, following promising results in Phase II when used in combination with the NS5A replication complex inhibitor elbasvir, either with or without ribavirin. Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets. It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications.
has abstract
Grazoprevir (MK-5172) is a dru ...... ly used antiviral medications.
@en
غرازوبريفير هو دواء يستخدم في ...... م زيباتيرمع أو بدون ريبافيرين.
@ar
CAS number
1350514-68-9
ChEBI
IUPAC name
(1R,18R,20R,24S,27S)-N-{(1R,2S ...... 7,9,11-pentaene-27-carboxamide
@en
PubChem
thumbnail
Wikipage page ID
46,273,530
Wikipage revision ID
733,972,758
ChemSpiderID
28,506,694
legal status
Investigational
molecular weight
7.66901e+2
routes of administration
smiles
O=C1CNCOC3CC3CCCCCc2nc4ccccc4nc2OCCN1C6CNC5CNSC7CC7
hypernym
comment
Grazoprevir (MK-5172) is a dru ...... ly used antiviral medications.
@en
غرازوبريفير هو دواء يستخدم في ...... م زيباتيرمع أو بدون ريبافيرين.
@ar
label
Grazoprevir
@en
غرازوبريفير
@ar